VN1R91P: A Drug Target / Disease Biomarker (G100312836)

Target Name: VN1R91P

NCBI ID: G100312836

VN1R91P

Other Name(s): Vomeronasal 1 receptor 91 pseudogene | vomeronasal 1 receptor 91 pseudogene

VN1R91P: A Drug Target / Disease Biomarker

VN1R91P is a protein that is expressed in the human placenta and has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is derived from the vitamin K antagonist NKG2D, which is a well-known drug for the treatment of bleeding disorders.

VN1R91P is a member of the NKG2D family, which is characterized by the presence of a unique N-terminal hypervariable region (HVR) that is involved in the inhibition of coagulation factors II and VII. This HVR is a key determinant of the protein's stability and functions as a drug target.

Studies have shown that VN1R91P is involved in various physiological processes in the human body, including cell signaling, angiogenesis, and inflammation. It has been shown to play a role in the regulation of platelet function, which is critical for the formation of blood clots that are essential for blood flow and oxygenation.

In addition to its role in platelet function, VN1R91P is also involved in the regulation of cell adhesion and migration. It has been shown to promote the migration of cancer cells to new sites of growth and has been identified as a potential therapeutic target for cancer.

The identification of VN1R91P as a potential drug target or biomarker for cancer has led to a significant amount of research into its properties and potential clinical applications. Studies have shown that VN1R91P can be effectively targeted by small molecules, including inhibitors of its N-terminus and C-terminus.

One of the most promising approaches for targeting VN1R91P is the use of small molecules that can inhibit its N-terminus. This approach has been shown to be effective in animal models of cancer and has potential for human clinical trials.

Another approach for targeting VN1R91P is the use of antibodies that can specifically recognize and target its HVR. This approach has been shown to be effective in animal models of cancer and has potential for human clinical trials.

In conclusion, VN1R91P is a protein that is expressed in the human placenta and has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is derived from the vitamin K antagonist NKG2D and is characterized by the presence of a unique N-terminal hypervariable region.

VN1R91P has been shown to play a role in various physiological processes in the human body, including cell signaling, angiogenesis, and inflammation. It has also been shown to promote the migration of cancer cells to new sites of growth, which makes it a potential therapeutic target for cancer.

The identification of VN1R91P as a potential drug target or biomarker for cancer has led to a significant amount of research into its properties and potential clinical applications. Studies have shown that VN1R91P can be effectively targeted by small molecules, including inhibitors of its N-terminus, and antibodies that can specifically recognize and target its HVR.

There is hope that VN1R91P will continue to be identified as a potential drug target or biomarker for cancer and will lead to human clinical trials that will evaluate its safety and effectiveness.

Protein Name: Vomeronasal 1 Receptor 91 Pseudogene

The "VN1R91P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VN1R91P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets